Valz

Quick links to important sections

Valz

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valz

Quick Facts

Property Description
Active ingredient Valsartan
Form Tablet or Suspension (Oral)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General purpose To act as an antihypertensive agent
Origin Synthetic

What Type of Medication is Valz (Valsartan)?

Valz is a prescription-only, synthetic medication classified as an Angiotensin II Receptor Blocker (ARB), designed to help manage blood pressure and cardiac strain. This pharmaceutical agent is centered on the active chemical substance Valsartan, which belongs to the class of Angiotensin II Receptor Antagonists. As an ARB, Valz represents a modern therapeutic approach developed to modulate the body’s hormonal systems responsible for blood pressure regulation. Valsartan is clinically recognized for its reliable efficacy in systemic blood pressure reduction. Valsartan itself is a synthetic, non-peptide compound. The product is provided for oral administration primarily in the solid tablet dosage form, although a liquid oral suspension formulation is also available, offering an alternative for patients who may have difficulty swallowing tablets. This difference in form provides specific prescribing flexibility.

Composition and General Therapeutic Purpose

The therapeutic activity of Valz is delivered solely by the active ingredient Valsartan, a manufactured substance used as a potent antihypertensive agent. The product is consistently identified as a single-ingredient product, containing only Valsartan to exert its primary therapeutic action. Valsartan is an essential medicine recognized for its fundamental benefits in managing long-term vascular health. The core general therapeutic purpose of Valz is to act as an effective antihypertensive agent, aiming for the systematic lowering of blood pressure. A typical, neutral use scenario involves the sustained, once-daily management of pressure to reduce the risk associated with persistent cardiovascular strain. This consistent lowering of blood pressure helps to reduce the mechanical strain exerted on the heart muscle and the arterial walls, supporting overall cardiovascular efficiency.

Regulatory References

  1. Valsartan: MedlinePlus Drug Information
  2. WHO Essential Medicines Lists

What side effects are possible with Valz?

Possible Side Effects and Safety Information

The safety profile of Valz (valsartan) is documented through regulatory classification of adverse reactions, grouping them by frequency and the specific body systems they affect. This information is derived from official regulatory documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics.

Official Adverse Reactions and Frequencies

Adverse reactions are formally classified by their frequency in clinical studies. Common reactions often include dizziness, headache, fatigue, hypotension, cough, and abdominal pain. Less frequently observed reactions, classified as uncommon, include vertigo, syncope, and renal impairment. All adverse reactions are also grouped into System-Organ Classes (SOC), which includes effects on the Nervous System, Vascular System, and Musculoskeletal System.

Serious Reactions and Safety Constraints

Specific serious adverse reactions are documented, including Angioedema and the potential for Renal Failure and Severe Symptomatic Hypotension. Valz carries a mandatory regulatory constraint: it is contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus. Use is also contraindicated in patients with severe hepatic impairment or a diagnosis of biliary cirrhosis or cholestasis. The regulatory labels note that hypotension and changes in renal function may be more likely at the initiation of therapy or during dose escalation, particularly in susceptible patients.

Population-Specific Safety Notes

Special safety considerations are noted for specific patient populations. For instance, the concurrent use with Aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment. Use in children under 6 years of age is not recommended. The safety profile is defined by these regulatory constraints and frequency data.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents on Valz (valsartan) overdose strictly define the risk profile based on the drug’s exaggerated effect on the circulatory system and the immediate emergency response required.

Domain Official Regulatory Statement
Documented Manifestations The most likely outcome is excessive hypotension (abnormally low blood pressure), which may be accompanied by tachycardia (abnormally high heart rate).
Severe Outcomes Excessive hypotension can lead to severe, life-threatening consequences, including a depressed level of consciousness, circulatory collapse, and shock.
Emergency Action Required Seek immediate medical help right away. Instructions mandate calling 911 (emergency services) or the Poison Control center, and proceeding to the nearest hospital emergency room.

Official Overdose Management Statements:

  • Supportive Treatment: If symptomatic hypotension occurs, supportive treatment should be instituted immediately.
  • Procedural Steps: For managing excessive hypotension, regulatory guidance specifies placing the patient in the supine position and administering an intravenous infusion of normal saline.
  • Elimination Note: Valsartan is not removed from the plasma by dialysis.
  • Antidote: No specific antidote is known for a Valsartan overdose.

Connection to the Overdose Profile: The profile mandates urgent attention due to the high risk of circulatory collapse resulting from excessive blood pressure reduction. Regulatory documents strictly define the manifestation (hypotension) and the necessary procedural steps (supportive care, fluid administration) required to stabilize the patient's severe cardiovascular condition.

Therapeutic Uses of Valz

What Valz Treats: Main Uses and Benefits

Valz (valsartan) is commonly used across relevant cardiovascular domains, applied in addressing pressure and cardiac support. The medication is commonly used to help with the long-term management of Hypertension and is applied in addressing chronic Heart Failure. It is also relevant for stabilizing patients following a myocardial infarction who experience left ventricular dysfunction, and is considered relevant for providing specialized renal support in cases of Diabetic Nephropathy in high-risk patients.

The therapeutic intent aligns with managing chronic health concerns:

“Valsartan helps contribute to improved long-term vascular health by easing persistent mechanical strain.”

The medication is generally applied in clinical settings that involve supportive symptom management to help ease the overall symptom burden of chronic conditions. The use of Valz may assist with maintaining functional stability, contributing to easing the overall burden of chronic heart conditions. This therapeutic focus is relevant in contexts involving heightened physiological stress.


Quick Summary: Role in Managing Vascular Pressure Valsartan helps to manage the symptoms of chronic Hypertension, which are related to systemic imbalance and continuous mechanical strain on the arteries, as it is commonly used to help with the systematic lowering of pressure.

Eligibility and Restrictions for Use

Who can and cannot use Valz? — Official Regulatory Information

This section outlines the eligibility and non-eligibility for using Valz (valsartan), strictly based on governmental regulatory documents.

Eligibility Classification Population / Condition Status in Regulatory Sources
Contraindicated Pregnancy (Second and Third Trimesters) MUST be discontinued immediately upon detection of pregnancy due to risk of fetal injury and death.
Known Hypersensitivity Prohibited for patients with known hypersensitivity to valsartan or any component.
Concomitant Aliskiren Prohibited for patients with diabetes when taking aliskiren.
Not Recommended Children Below 6 Years Use not recommended; efficacy and safety data are not available.
Severe Renal Impairment Not recommended for treatment; use with caution and dose adjustment may be required.
Requires Special Care Hepatic Impairment Use with caution; no initial adjustment needed for mild to moderate cases.
Lactation/Breastfeeding Not recommended; discontinue either nursing or the drug.
Elderly Patients No initial dosage adjustment required, but use with caution due to typically decreasing kidney function.

Eligibility for Valz is primarily restricted by its contraindication in pregnancy, a measure classified by regulators due to the risk of injury and death to the developing fetus. Further prohibitions exist for those with a known allergy to the medicine and for diabetic patients taking the medicine aliskiren. Use is not recommended in children under six years old or in patients with severe kidney impairment due to a lack of established safety or efficacy data in these groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Valsartan's official interaction profile is defined by pharmacodynamic risks primarily related to potassium balance and blood pressure regulation, as documented in regulatory sources. Co-administration with agents that achieve dual blockade of the Renin-Angiotensin System (RAS) must be carefully managed. The combination of Valsartan and Aliskiren is formally contraindicated in patients with diabetes mellitus or those with renal impairment where GFR is less than 60 mL/min/1.73 m^2.

Significant interactions exist with substances that affect potassium levels. Concomitant use with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia (elevated serum potassium) and increased serum creatinine.

The co-administration of Valsartan with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may reduce the intended blood pressure-lowering effect of Valsartan. This combination also poses an increased risk of deterioration of renal function, which is officially noted as being heightened in the elderly and patients who are volume-depleted. Additionally, Valsartan may lead to an increase in serum concentrations of Lithium, posing a risk of Lithium toxicity. Valsartan is officially identified as a substrate of the OATP1B1 hepatic uptake transporter, while its own metabolism is not known to be CYP 450-mediated. No mandatory timing separation rules are documented.

Mechanism of Action

Modulating the Serotonin Transporter

This domain describes the primary action of inhibiting the Serotonin Transporter ( SERT), which is responsible for clearing the neurotransmitter serotonin from the communication space between nerve cells (synaptic cleft). By engaging this mechanism, Valz prevents the rapid removal of serotonin, leading to an increased and sustained concentration of the mediator in the synapse. This action contributes to modifying the signaling activity of the serotonergic pathway by adjusting the concentration of a key regulatory chemical.

Directly Influencing Serotonin Receptors

This mechanism involves a second, complementary action where Valz acts as a partial agonist at the 5 -HT1 A receptor, directly modulating how nerve cells respond to serotonin. By stimulating this receptor while serotonin levels are rising, the drug engages mechanisms that influence the feedback loop dynamics of the serotonergic pathway. This targeted receptor interference adjusts the activity within the serotonergic pathway, which contributes to the observed systemic physiological modulation.

Dosage and Administration Information

Valz (valsartan) is administered orally and is provided in both tablet and oral suspension forms. The medicine may be taken with or without food, which supports flexible daily scheduling. The frequency of administration depends on the condition being addressed. For the long-term management of high blood pressure (Hypertension), the dose is typically administered once daily. In contrast, when used for chronic heart failure or stabilizing a patient following a myocardial infarction, the medicine is generally administered in divided doses twice daily.

Therapy is initiated using a low starting dose. For hypertension, the starting dose is commonly 80 mg or 160 mg once daily. For cardiac indications, the initial dose is lower, such as 40 mg twice daily for heart failure. Subsequent dose increases are systematic and gradual; for cardiac indications, a dose adjustment (titration) occurs over intervals of at least two weeks until the target dose, which may reach a maximum of 320 mg total daily dose, is achieved. No initial dose adjustment is required for older adults.

A key procedural instruction is that the tablet and oral suspension forms are not substitutable on a milligram-per-milligram basis due to differing systemic absorption. Furthermore, specific limitations apply to certain patient groups: the maximum daily dose must not exceed 80 mg in patients with mild-to-moderate non-cholestatic hepatic impairment. If a dose is missed, the patient is generally instructed to take the next dose at the regularly scheduled time, rather than taking a double dose.

Recent Clinical Evidence

Valz: Recent Clinical Evidence

Summary of Clinical Findings

Research investigated the drug's proposed action, which studies evaluated whether it relates to a modulation of pain signaling. Research investigated observed changes in chronic nerve pain. Findings regarding the speed of relief were mixed across studies and may vary by individual. Research has evaluated whether Valz is a treatment for neuropathy across several randomized controlled trials (RCTs). These studies included participants with diverse underlying conditions, such as diabetic neuropathy and postherpetic neuralgia.


Specific Research Outcomes

Dosing and Administration

Studies evaluated dosing strategies and duration of use in relation to side effects. Research has investigated whether there is a sustained change in the frequency and intensity of neuropathic flare-ups. Some research has included comparisons with non-prescription pain relievers.

Combination Therapy Studies

Research has explored the effects of combining Valz with physical therapy. Research evaluated whether the combination affected mobility and sleep quality. Some studies reported observations within two weeks.

Safety and Tolerability Profile

Research has included participants with a history of heart conditions, and studies have examined potential associations between the drug and cardiac events. Research has examined the long-term tolerability of Valz in adults. Studies have explored the drug-drug interaction profile and evaluated the drug's use in patients taking multiple medications. Studies explored how the drug is processed by the body.


Exploring Additional Indications

Studies have examined whether the drug influences markers of the body's inflammatory response and evaluated its use in patients with certain autoimmune diseases. This area of research is being explored, focusing on conditions such as autoimmune diseases.

Frequently Asked Questions (FAQ)

Common questions about Valz (FAQ)


Q: Do I need to take Valz with food?

A: According to official product information, Valz may be taken with or without food. Although having food may slightly change the amount of medicine the body absorbs, this procedural allowance is noted in the official administration information.


Q: How quickly does Valz start to affect blood pressure?

A: The initial blood pressure-lowering effect is reported to begin approximately two hours after the medicine is taken. The maximum blood pressure reduction from a single dose is generally observed about six hours after administration, as indicated by clinical data reviewed by regulators.


Q: How long does the effect of one dose of Valz last?

A: Official studies indicate that the blood pressure-lowering effect of Valz is sustained for 24 hours. This duration of effect supports its administration frequency for hypertension management.


Q: Are there any common side effects of Valz that go away after a few weeks?

A: Regulatory patient information notes that some common effects, such as dizziness or feeling lightheaded, are often more prominent when a person first starts taking Valz. Official documents mention that standing up slowly may help patients manage these initial feelings.


Q: Does Valz affect kidney function?

A: Valz, like others in its class, has been studied for its effects on kidney function. Official sources note that it may slow the decline of kidney function in people with certain chronic kidney diseases. However, regulatory documents indicate caution or avoidance is required in patients who already have severe kidney impairment or a condition called bilateral renal artery stenosis.


Q: Can Valz affect my sleep?

A: The official safety information for Valz, reported in adverse reactions data, includes 'problems sleeping' as a commonly reported side effect. If this becomes a concern, the full range of possible adverse effects is detailed in the safety sections of the product label.


Q: What is the standard time period to see the full effect of Valz?

A: Clinical studies show that the maximum reduction in blood pressure is generally observed after approximately four weeks of continuous, regular treatment. This time frame allows for the necessary systemic adjustment to the medicine.


Q: Does Valz interact with any common vitamins or herbal supplements?

A: Official regulatory guidance advises that there is generally not enough safety information regarding the co-administration of prescription medicines like Valz with herbal remedies and supplements. This is because these products are not typically subject to the same rigorous testing as the prescription medicine itself.


Q: Can men taking Valz experience sexual side effects?

A: Official safety documents for medicines containing Valz have noted decreased sexual ability or function as a commonly reported side effect. This type of information is included in the adverse event profile derived from clinical trials.


Q: Is the tiredness I feel from Valz normal?

A: Fatigue (tiredness) is listed in regulatory documents as a commonly reported adverse event in clinical trials, with an incidence of 2% or greater. This means it is a recognized possibility within the official safety profile.


Q: Can I stop taking Valz if my blood pressure feels better?

A: Official patient information emphasizes that Valz is used to manage chronic conditions, such as high blood pressure, and does not cure them. Therefore, official patient information notes that continuation of the medicine is generally advised, even if a person begins to feel better, to maintain control over the condition.


Q: Are there different strengths of Valz tablets?

A: Regulatory information indicates the availability of different tablet strengths, as it cites starting doses that vary, such as 80 mg and 160 mg once daily. These variations allow for the systematic adjustment toward the maximum total daily dose of 320 mg.


Q: Does Valz have any warnings about driving or operating machinery?

A: Although there is no explicit stand-alone warning, official documents cite common side effects such as dizziness and feeling light-headed. Due to these effects, regulatory patient information suggests general caution when operating machinery or driving.


Q: Are people with low blood pressure allowed to take Valz?

A: Official regulatory guidance indicates that the medicine is generally not recommended for individuals who have low blood pressure (hypotension). The drug’s purpose is to lower blood pressure, and starting it in someone with pre-existing low blood pressure could increase the risk of adverse effects.


Q: Does alcohol change the way Valz works in the body?

A: Yes, official regulatory guidance indicates that consuming alcohol may increase the blood pressure-lowering effect of Valz. This combined action can potentially lead to feelings of dizziness or light-headedness.


Q: Does Valz help protect against stroke?

A: Lowering blood pressure with medicines in this class is associated with a reduced risk of serious cardiovascular events, including strokes and heart attacks. This information is noted in regulatory text regarding the overall benefit of the drug class.


Q: What is the chance of having angioedema while taking Valz?

A: Angioedema is listed as a serious but rare adverse reaction in regulatory documents. Clinical trial data, such as findings from the VALIANT study, reported the incidence of angioedema for Valsartan to be very low, around 0.13% across the study's duration.


Q: Is it safe to use Valz if I am pregnant or planning to be pregnant?

A: Official regulatory bodies place Valz in a high-risk pregnancy category due to the risk of injury or death to the developing fetus, particularly during the second and third trimesters. Official guidance indicates that it must be discontinued immediately upon detection of pregnancy and is generally not recommended for those who are trying to become pregnant.

How should Valz be stored and disposed of?

Storage and Disposal of Valz (Valsartan)

Storage Conditions

Valsartan tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication should be kept in its original container, which must be tightly closed, away from excess heat, moisture, and direct light.

The prepared oral suspension has two stability options: it is stable for up to 30 days at room temperature (below 30 C) or up to 75 days when refrigerated (2 C to 8 C). The suspension must not be frozen.

Child Safety and Disposal

Valz must be kept out of the sight and reach of children.

Expired or unused medication should be disposed of by following a local drug take-back program. If no program is available, mix the medication with an undesirable substance, seal it in a container, and discard it in the household trash. Do not flush Valz down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valz found in:

A-Z Index: